GERN - Geron Corporation
Geron Corporation
919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 107
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. John A. Scarlett M.D. | Chairman, Pres & CEO | 1.53M | N/A | 1951 |
| Ms. Olivia Kyusuk Bloom | Exec. VP of Fin., CFO & Treasurer | 826.02k | N/A | 1969 |
| Dr. Andrew J. Grethlein | Exec. VP & COO | 847.2k | N/A | 1964 |
| Ms. Aron Feingold | VP of Investor Relations & Corp. Communications | N/A | N/A | N/A |
| Mr. Stephen N. Rosenfield J.D. | Exec. VP, Chief Legal Officer & Corp. Sec. | N/A | N/A | 1950 |
| Ms. Shannon Odam | VP of HR | N/A | N/A | N/A |
| Ms. Melissa A. Kelly Behrs | Exec. VP of Bus. Operations & Chief Alliance Officer | N/A | N/A | 1964 |
| Mr. Anil Kapur | Exec. VP of Corp. Strategy & Chief Commercial Officer | N/A | N/A | 1970 |
| Mr. Edward E. Koval | Exec. VP & Chief Bus. Officer | N/A | N/A | 1962 |
| Dr. Faye Feller M.D. | Exec. VP & Chief Medical Officer | N/A | N/A | 1982 |
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Corporate governance
Geron Corporation’s ISS governance QualityScore as of 1 May 2023 is 6. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 7; Compensation: 6.
